Our Atlantis Health Australia team, in collaboration with Swedish Orphan Biovitrum (Sobi) Australia, have proudly received a Highly Commended award for Excellence in Patient Support at the 2023 PRIME Awards for the EMPower Support Ecosystem. EMPower is a wrap-around, personalized support service co-designed with and for people living with the ultra-rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH), helping them to initiate treatment and manage the impact of PNH.
The PRIME Awards is an annual event that recognizes and celebrates excellence across 18 categories within healthcare communications and the Australian pharmaceutical and life sciences industry.
"We are proud to be recognized as Highly Commended with our partner Sobi, and for the positive impact we’re making for all those involved in managing people living with PNH during their treatment journey," said Nathan O’Donnell, Atlantis Health ANZ Country Manager. "Core to our success was closely understanding and anticipating the needs and challenges of patients, their families and healthcare professionals, and developing solutions that encompass all aspects of the management of PNH and treatment.”
"Sobi is delighted to see EMPower being awarded Highly Commended in the category of Excellence in Patient or Customer Support at the PRIME Awards 2023. We’ve partnered with Atlantis Health to understand the needs of the PNH community including HCPs, the patients they treat and their carers, to identify the PNH treatment journey. By embracing Sobi’s core values of care and partnership, we have been able to design and implement an ecosystem of support with the EMPower Program" - Sharon Lo, Patient Services Manager, Swedish Orphan Biovitrum Pty Ltd (Sobi)
Sobi and Atlantis Health also recently shared EMPower at the 2023 Blood annual hematology conference in Melbourne, Australia.